Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma Publication Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…CertaraAugust 13, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial Publication Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…CertaraAugust 13, 2025
Certara Announces D360 25.5 Release, Featuring Dynamic Data Subsets and Enhanced Analytics Announcement Certara Announces D360 25.5 Release, Featuring Dynamic Data Subsets and Enhanced Analytics D360 v25.5 allows scientists to divide up a dataset into series of compounds & perform…CertaraAugust 7, 2025
De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator Webinar De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator CertaraAugust 5, 2025
Understanding Antibody-Drug Conjugates (ADCs) Pharmacokinetics From NCA to Population PK Approaches Webinar Understanding Antibody-Drug Conjugates (ADCs) Pharmacokinetics From NCA to Population PK Approaches CertaraAugust 1, 2025
Machine Learning (ML) in healthcare Blog Machine Learning (ML) in healthcare Learn about 3 distinct examples of machine learning (ML) in healthcare that utilize different techniques…CertaraAugust 1, 2025
Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials Blog Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…CertaraJuly 31, 2025
Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development Case Study Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development Certara supported DMD drug development for Givinostat, helping Italfarmaco with pharmacometric and regulatory strategy.CertaraJuly 29, 2025
AusBiotech International Conference 2025 Conference AusBiotech International Conference 2025 Danielle PillsburyJuly 25, 2025
ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered Blog ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…CertaraJuly 23, 2025